Viridian Therapeutics, Inc. (VRDN) Q3 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to Viridian Therapeutics third quarter 2022 earnings call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host. John Jordan, Vice President of Investor Relations. Please go ahead. Thank you, Brock. Good morning, everyone, and welcome to the Viridian conference call to discuss the positive clinical data report earlier today for VRDN001 in patients with thyroid eye disease. Before we begin, I'd like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from Those expressed in or implied by such forward-looking statements are discussed in greater detail in our most recent filings on Form 10-K and 10-Q and other reports on file with the SEC. I'm joined today by Dr. Jonathan Violin, President and CEO, Dr. Barry Katz, our Chief Medical Officer, and Christian Humer, our Chief Financial Officer and Chief Business Officer. I would now like to turn the call over to Jonathan. Thanks, John, and good morning, everyone. Thanks for joining us. Over the last quarter, Viridian continued to ...